Central Bank & Trust’s Edwards Lifesciences EW Stock Holding History

Central Bank & Trust’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,023	Closed	-$279K	–	245
2024 Q2	$279K	Hold	3,023	–	–	0.04%	159
2024 Q1	$289K	Hold	3,023	–	–	0.04%	162
2023 Q4	$231K	Buy	+3,023	New	+$210K	0.04%	169
2023 Q2	–	Sell	-33	Closed	-$2.73K	–	362
2023 Q1	$2.73K	Buy	+33	New	+$2.59K	﹤0.01%	335
2022 Q3	–	Sell	-39	Closed	-$4K	–	319
2022 Q2	$4K	Buy	+39	New	+$4.04K	﹤0.01%	300
2022 Q1	–	Sell	-392	Closed	-$51K	–	319
2021 Q4	$51K	Hold	392	–	–	0.01%	228
2021 Q3	$44K	Hold	392	–	–	0.01%	228
2021 Q2	$41K	Hold	392	–	–	0.01%	228
2021 Q1	$33K	Buy	+392	New	+$33.1K	0.01%	228
2019 Q2	–	Sell	-186	Closed	-$12K	–	266
2019 Q1	$12K	Hold	186	–	–	﹤0.01%	221
2018 Q4	$9K	Sell	186 -99	-35%	-$5.01K	﹤0.01%	221
2018 Q3	$17K	Buy	+285	New	+$13.9K	﹤0.01%	209
2017 Q2	–	Sell	-42	Closed	-$1K	–	288
2017 Q1	$1K	Hold	42	–	–	﹤0.01%	321
2016 Q4	$1K	Sell	42 -222	-84%	-$7.19K	﹤0.01%	315
2016 Q3	$11K	Buy	+264	New	+$9.94K	﹤0.01%	251

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Central Bank & Trust's EW Position: Q3 2024 in Review

Central Bank & Trust sold out of Edwards Lifesciences (EW) in Q3 2024, closing a stake of 3,023 shares — an estimated $279K sold.

Central Bank & Trust first reported a position in EW in Q3 2016 and held it in 15 quarters. The position peaked at $289K in Q1 2024. 1,195 funds tracked by Wall St. Rank hold EW as of Q3 2024.

Central Bank & Trust reported no remaining Edwards Lifesciences position as of Q3 2024 after selling out during the quarter.
Central Bank & Trust sold 3,023 Edwards Lifesciences shares in Q3 2024, an estimated $279K.
Central Bank & Trust first reported a position in Edwards Lifesciences in Q3 2016 and held it in 15 quarters.
Central Bank & Trust's Edwards Lifesciences position peaked at $289K in Q1 2024.
1,195 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2024.

Based on Central Bank & Trust's 13F filing for Q3 2024, filed 30 Oct 2024.